Anti-IGSF1 antibody and its use

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
An anti-IGSF1 antibody targeting the C-terminus of IGSF1 enhances immune response and inhibits tumor growth by increasing immune cell infiltration, addressing the limitations of current cancer treatments.

JP7864075B2Active Publication Date: 2026-05-22WELLMARKER BIO CO LTD

View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office: JP · JP
Patent Type: Patents
Current Assignee / Owner: WELLMARKER BIO CO LTD
Filing Date: 2021-08-20
Publication Date: 2026-05-22

Application Information

Patent Timeline

20 Aug 2021

Application

22 May 2026

Publication

JP7864075B2

IPC: A61K39/395; C12N15/13; C12N15/63; C12N5/10; C12N1/19; C12N1/21; C12N1/15; C07K16/28; C12P21/08; A61P35/00

CPC: A61P35/00; A61K2039/505; C07K16/2803; C07K2317/92; C07K2317/21; C07K2317/73; C12N15/85; C07K2317/565

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

AI Technical Summary

Technical Problem

Current cancer treatments, including chemotherapy and existing diagnostic technologies, have limited efficacy against diverse cancer pathologies and often result in recurrence and metastasis, necessitating the development of targeted therapies that address biomarkers like IGSF1 to improve treatment outcomes.

Method used

Development of an anti-IGSF1 antibody that specifically binds to the C-terminus of IGSF1, which is overexpressed in various cancers, enhancing immune cell infiltration and immune response to inhibit tumor growth.

Benefits of technology

The anti-IGSF1 antibody increases immune cell infiltration and cytokine expression in tumor tissues, effectively suppressing tumor growth in lung cancer models with high IGSF1 expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

Figure 0007864075000003
Figure 0007864075000004
Figure 0007864075000005

Patent Text Reader

Abstract

The present invention relates to a novel antibody that specifically binds to IGSF1, and a pharmaceutical composition for preventing or treating cancer, comprising the antibody as an active ingredient. In particular, the present invention provides an antibody that binds to the C-terminus of IGSF1. The anti-IGSF1 antibody according to the present invention showed high specificity and high binding ability to IGSF1. When lung cancer cell spheroids in which IGSF1 is overexpressed were co-cultured with human peripheral mononuclear cells, the anti-IGSF1 antibody according to the present invention increased the infiltration of immune cells into the spheroids. In addition, the anti-IGSF1 antibody according to the present invention inhibited tumor growth and increased the expression of cytokines in tumor tissues in humanized mice transplanted with human lung cancer cells in which IGSF1 is overexpressed. From the above results, it was confirmed that the anti-IGSF1 antibody can inhibit tumor growth by increasing the infiltration of immune cells and immune responses into lung cancer tissues in which IGSF1 expression is increased. Therefore, the anti-IGSF1 antibody can be used as an anticancer agent for effectively treating cancers in which IGSF1 is overexpressed.

Need to check novelty before this filing date? Find Prior Art